There is increasing interest in the application of biomarkers and surrogate endpoints in healthy volunteer studies.
Biomarkers provide pivotal information on efficacy, dose-response and time-effects of drugs. ICON has worked extensively in this area, developing and validating pharmacodynamic models for investigating a range of therapeutic targets, as part of its own research and development efforts and in partnership with Sponsors. These specialist techniques fall broadly into two categories.
PD Models of Disease State
Use of healthy volunteer models has proven to be fast and reliable for determining if a drug has the necessary characteristics to be taken forward into more expensive patient trials. The dedicated Clinical Pharmacodynamics group at ICON has developed and validated a variety of pharmacodynamic models in a broad range of therapeutic areas, including:
Techniques for Specific PD Responses
When a protocol requires the inclusion of a specific technique that is out of the normal scope of a CPU, the PD group is responsible for identifying, validating and testing the equipment. A wide list of techniques is offered by ICON covering tests for sedation, CNS imaging, physiological assessments and mood assessments.
Factsheet: Clinical Pharmacodynamics
The pharmaceutical industry itself has a growing pressure to develop medicines more quickly and cost-effectively with early read-outs on putative efficacy or potential development obstacles obtained. Discover how our cutting edge pharmacodynamic models can provide this for you.